You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Why is the Omvoh® (mirikizumab-mrkz) Crohn's disease maintenance dose 2 injections?
In the mirikizumab Crohn's disease clinical development program, participants received a full maintenance dose through one 2-mL injection and one 1-mL injection. The efficacy of a single 3-mL injection has not been evaluated.
Maintenance Dosage and Administration of Mirikizumab for Crohn's Disease
The recommended maintenance dosage of mirikizumab for the treatment of Crohn's disease is 300 mg administered by subcutaneous injection, given as 2 consecutive injections of 100 mg and 200 mg, at week 12, and every 4 weeks thereafter.1
Mirikizumab for the treatment of Crohn's disease is available for subcutaneous injection as 200 mg/2 mL plus 100 mg/mL solution in a single-dose prefilled pen, or as 200 mg/2 mL (100 mg/mL) plus 100 mg/mL solution in a single-dose prefilled syringe.1
Enclosed Prescribing Information
Reference
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: January 15, 2025